Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Rambaldi, Alessandro  [Clear All Filters]
2019
Sorà, F., Di Grazia, C., Chiusolo, P., Raiola, A.Maria, Bregante, S., Mordini, N., Olivieri, A., Iori, A.Paola, Patriarca, F., Grisariu, S., et al. (2019). Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with Busulfan Fludarabine (BUFLU) or Thiotepa Busulfan Fludarabine (TBF): a retrospective study.Biol Blood Marrow Transplant.
Stein, A.S., Kantarjian, H., Gökbuget, N., Bargou, R., Litzow, M.R., Rambaldi, A., Ribera, J.-M., Zhang, A., Zimmerman, Z., Zugmaier, G., et al. (2019). Blinatumomab for Acute Lymphoblastic Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant.
Candoni, A., Rambaldi, A., Fanin, R., Velardi, A., Arcese, W., Ciceri, F., Lazzarotto, D., Lussana, F., Olivieri, J., Grillo, G., et al. (2019). Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Societ.Biol Blood Marrow Transplant.
Marchetti, M., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Rossi, E., Betti, S., Di Veroli, A., Iurlo, A., et al. (2019). Second cancers in MPN: survival analysis from an international study.Am J Hematol.
Beelen, D.Wilhelm, Trenschel, R., Stelljes, M., Groth, C., Masszi, T., Reményi, P., Wagner-Drouet, E.-M., Hauptrock, B., Dreger, P., Luft, T., et al. (2019). Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 .Lancet Haematol.
2018
Patriarca, F., Masciulli, A., Bacigalupo, A., Bregante, S., Pavoni, C., Finazzi, M.Chiara, Bosi, A., Russo, D., Narni, F., Messina, G., et al. (2018). Busulfan or thiotepa based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group.Biol Blood Marrow Transplant.
Robin, M., Porcher, R., Ruggeri, A., Blaise, D., Wolschke, C., Koster, L., Angelucci, E., Stölzel, F., Potter, V., Yakoub-Agha, I., et al. (2018). HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis.Biol Blood Marrow Transplant.
2016
Efficace, F., Mandelli, F., Fazi, P., Santoro, C., Gaidano, G., Cottone, F., Borchiellini, A., Carpenedo, M., Simula, M.Pina, Di Giacomo, V., et al. (2016). Health-Related Quality of Life and Burden of Fatigue in Patients with Primary Immune Thrombocytopenia by Phase of Disease.Am J Hematol.
2015
Salati, S., Zini, R., Nuzzo, S., Guglielmelli, P., Pennucci, V., Prudente, Z., Ruberti, S., Rontauroli, S., Norfo, R., Bianchi, E., et al. (2015). Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis.Int J Cancer.
Girmenia, C., Viscoli, C., Piciocchi, A., Cudillo, L., Botti, S., Errico, A., Sarmati, L., Ciceri, F., Locatelli, F., Giannella, M., et al. (2015). Management of carbapenem resistant klebsiella pneumoniae infections in stem cell transplant recipients: an italian multidisciplinary consensus statement.Haematologica.
Galli, M., Lessi, F., Rambaldi, A., Fedrigo, M., De Rosa, G., and Adami, F. (2015). Mobilization of peripheral blood hematopoietic stem cells by granulocyte-colony stimulating factor and plerixafor in patients with cardiac AL amyloidosis.Amyloid1-2.
2014
Capelli, C., Pedrini, O., Cassina, G., Spinelli, O., Salmoiraghi, S., Golay, J., Rambaldi, A., Giussani, U., and Introna, M. (2014). Frequent non-malignant genetic alterations occurrence in clinical grade Mesenchymal Stromal Cells expanded for Cell Therapy Protocols.Haematologica.
Pagani, I.S., Spinelli, O., Mattarucchi, E., Pirrone, C., Pigni, D., Amelotti, E., Lilliu, S., Boroni, C., Intermesoli, T., Giussani, U., et al. (2014). Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia.Oncoscience1, 510-21.
Norfo, R., Zini, R., Pennucci, V., Bianchi, E., Salati, S., Guglielmelli, P., Bogani, C., Fanelli, T., Mannarelli, C., Rosti, V., et al. (2014). miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis.Blood.
Rondelli, D., Goldberg, J.D., Isola, L., Price, L.S., Shore, T.B., Boyer, M., Bacigalupo, A., Rambaldi, A., Scarano, M., Klisovic, R.B., et al. (2014). MPD-RC 101 prospective study of reduced intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.Blood.
Porta, M.G.Della, Alessandrino, E.Paolo, Bacigalupo, A., van Lint, M.Teresa, Malcovati, L., Pascutto, C., Falda, M., Bernardi, M., Onida, F., Guidi, S., et al. (2014). Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R).Blood.
Lussana, F., and Rambaldi, A. (2014). Role of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia.Mediterr J Hematol Infect Dis6, e2014065.
Brissot, E., Labopin, M., Beckers, M.M., Socié, G., Rambaldi, A., Volin, L., Finke, J., Lenhoff, S., Kröger, N., Ossenkoppele, G.J., et al. (2014). Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Haematologica.